Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of CagriSema in Participants With Overweight or Obesity
NCT06388187Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2024
- Primary completion
- Apr 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
A Phase 3 trial of CagriSema in obesity, sponsored by Novo Nordisk. Started Jun 2024; status: completed.
02
Drugs
CagriSema
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06388187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06388187.